AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

MoS Health Jadhav inaugurates FSSAI’s stakeholder consultation on sustainable packaging

Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation

Shin-Etsu Chemical and Hokkaido University develop lipid nanoparticle production system capable of both small-batch, high-mix production

CCI approves merger between Aster DM Healthcare and Quality Care India

The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone

Injection filter needle market to reach $1.73 billion in 2025

Rising demands and advancements in eye care drive growth

Fortis Healthcare launches Fortis Institute of Genomic Medicine

Genomics is transforming the future of modern medicine and treatment modalities across specialties

Nissan Chemical extends supply agreement with MSD Animal Health for Fluralaner

Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,

Aurolife Pharma gets 11 observations from USFDA for Raleigh plant

The company does not expect this development to have any material impact on the current business operations

Shaik Barak Tulla joins Sun Pharma as Sr. VP

Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla

Fredun secures tender from TNMSC for supply of generic pharma products

The supply of these goods is set to commence within the first quarter of FY26